Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.96 EUR
Change Today 0.00 / 0.00%
Volume 0.0
NRST On Other Exchanges
As of 11:30 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

neurosoft (NRST) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/8/15 - €2.38
52 Week Low
04/28/14 - €1.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEUROSOFT (NRST)

Related News

No related news articles were found.

neurosoft (NRST) Related Businessweek News

No Related Businessweek News Found

neurosoft (NRST) Details

Neurosoft Software Production Société Anonyme designs, develops, customizes, and maintains integrated software systems in the areas of sports betting and gaming analytics, business intelligence, and core factoring in Greece and internationally. It also provides advanced information technology services. The company operates in four segments: Business Intelligence, Core Factoring, Sports Betting & Gaming Analytics, and Telecommunications. The Business Intelligence segment develops, markets, and supports an integrated line of statistical software products that enable its clients to bring marketplace and enterprise data together to bear on their decision-making. The Core Factoring segment offers Proxima+, a business factoring software solution to assist factoring companies. The Sports Betting & Gaming Analytics segment provides business intelligence solutions, which offer liability monitoring capabilities to betting operators. The Telecommunications segment sells and services telecommunication integrated equipment. In addition, the company’s products include Tesla, an online informational platform for clients and debtors; betting operators liability toolbox, a real-time view of an operator’s liability picture that enables the trader to implement their on-the-spot trading strategy; and OBERON, a transactional system, which allows two-way communication between disparate systems. Further, it offers Qualytor, a product that through the use of a multilingual and continuously updated database provides information for approximately 6,500 teams in football, basketball, and other sports. Neurosoft Software Production Société Anonyme was founded in 1994 and is based in Athens, Greece.

70 Employees
Last Reported Date: 04/8/15
Founded in 1994

neurosoft (NRST) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

neurosoft (NRST) Key Developments

Neurosoft Software Production Société Anonyme Announces Audited Consolidated Earnings Results for the Year Ended December 31, 2014

Neurosoft Software Production Société Anonyme announced audited consolidated earnings results for the year ended December 31, 2014. For the period, the company reported revenues were €10,271,403 compared to €5,842,269 a year ago. Profit before income taxes was €2,556,197 compared to €1,002,702 a year ago. Net Profit was €2,779,420 compared to €723,362 a year ago. Profit attributable to equity holders of the parent was €2,734,469 compared to €643,026 a year ago. Net cash from operating activities was €1,250,274 compared to €2,402,899 a year ago. Capital expenditure for property, plant and equipment was €986,334 compared to €221,119 a year ago. Net financial debt as of 31 December 2014 for the Group amounts to €1.47 million compared to €1.19 million as of 31 December 2013.

Caputron Medical, LLC. Inks Distribution Agreement with Neurosoft LTD

Caputron Medical announced it has entered into an agreement to distribute Neurosoft products for Transcranial Magnetic Stimulation. The distribution agreement brings Caputron Medical the rights to market the Neuro-MS/D Diagnostic, Therapeutic, and Advanced Therapeutic rTMS stimulators in the United States and Canada. Neurosoft TMS systems combine features and performance not available in any other TMS product, packaged in high-value systems for customers. These unique performance features include an unparalleled high-performance cooling system capable of performing up to 10,000 pulses during one session, a peak magnetic field of up to 4 Tesla and 20 Hz stimulation with 100% intensity. Neurosoft products are used internationally at medical research centers in the study of the non-invasive neuromodulation with applications areas in psychiatry, neurology, cognitive neuroscience, clinical neurophysiology and rehabilitation.

Neurosoft Software Production Société Anonyme to Report Fiscal Year 2014 Results on Apr 06, 2015

Neurosoft Software Production Société Anonyme announced that they will report fiscal year 2014 results at 10:30 AM, E. Europe Standard Time on Apr 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NRST:IM €1.96 EUR 0.00

NRST Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NRST.
View Industry Companies

Industry Analysis


Industry Average

Valuation NRST Industry Range
Price/Earnings 16.5x
Price/Sales 4.5x
Price/Book 8.6x
Price/Cash Flow 16.5x
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROSOFT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at